ACF Investors: Why raising EIS limits is a budget imperative

24 Nov

Written By Alexandra Collingbourne

Thought-piece

Alexandra Collingbourne

In conversation with David Cleevely: Serendipity: It Doesn't Happen by Accident

T-Therapeutics announces Series A extension to $91 million to advance first-in-class bispecifics towards the clinic